BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vita G, Vita GL, Stancanelli C, Gentile L, Russo M, Mazzeo A. Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies. Neurol Sci 2019;40:661-9. [DOI: 10.1007/s10072-019-03778-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Gentile L, Russo M, Taioli F, Ferrarini M, Aguennouz M, Rodolico C, Toscano A, Fabrizi GM, Mazzeo A. Rare among Rare: Phenotypes of Uncommon CMT Genotypes. Brain Sci 2021;11:1616. [PMID: 34942918 DOI: 10.3390/brainsci11121616] [Reference Citation Analysis]
2 Russo M, Gentile L, Di Stefano V, Di Bella G, Minutoli F, Toscano A, Brighina F, Vita G, Mazzeo A. Use of Drugs for ATTRv Amyloidosis in the Real World: How Therapy Is Changing Survival in a Non-Endemic Area. Brain Sci 2021;11:545. [PMID: 33925301 DOI: 10.3390/brainsci11050545] [Reference Citation Analysis]
3 Alonso-Pérez J, González-Quereda L, Bello L, Guglieri M, Straub V, Gallano P, Semplicini C, Pegoraro E, Zangaro V, Nascimento A, Ortez C, Comi GP, Dam LT, De Visser M, van der Kooi AJ, Garrido C, Santos M, Schara U, Gangfuß A, Løkken N, Storgaard JH, Vissing J, Schoser B, Dekomien G, Udd B, Palmio J, D'Amico A, Politano L, Nigro V, Bruno C, Panicucci C, Sarkozy A, Abdel-Mannan O, Alonso-Jimenez A, Claeys KG, Gomez-Andrés D, Munell F, Costa-Comellas L, Haberlová J, Rohlenová M, Elke V, De Bleecker JL, Dominguez-González C, Tasca G, Weiss C, Deconinck N, Fernández-Torrón R, López de Munain A, Camacho-Salas A, Melegh B, Hadzsiev K, Leonardis L, Koritnik B, Garibaldi M, de Leon-Hernández JC, Malfatti E, Fraga-Bau A, Richard I, Illa I, Díaz-Manera J. New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy. Brain 2020;143:2696-708. [PMID: 32875335 DOI: 10.1093/brain/awaa228] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
4 Gentile G, Cavallaro S. Translational Medicine in Neurological Disorders: A Genomic Perspective. Curr Genomics 2019;20:151-3. [PMID: 31929723 DOI: 10.2174/138920292003190704143857] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Russo M, Cucinotta F, Gentile L, Fabrizi GM, Taioli F, Vita G, Toscano A, Mazzeo A. Very Early Onset of ATTRE89Q Amyloidosis in a Homozygous Patient. TONEUJ 2021;15:21-4. [DOI: 10.2174/1874205x02115010021] [Reference Citation Analysis]
6 Vita GL, Aguennouz M, Polito F, Oteri R, Russo M, Gentile L, Barbagallo C, Ragusa M, Rodolico C, Di Giorgio RM, Toscano A, Vita G, Mazzeo A. Circulating microRNAs Profile in Patients With Transthyretin Variant Amyloidosis. Front Mol Neurosci 2020;13:102. [PMID: 32655365 DOI: 10.3389/fnmol.2020.00102] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
7 Russo M, Obici L, Bartolomei I, Cappelli F, Luigetti M, Fenu S, Cavallaro T, Chiappini MG, Gemelli C, Pradotto LG, Manganelli F, Leonardi L, My F, Sampaolo S, Briani C, Gentile L, Stancanelli C, Di Buduo E, Pacciolla P, Salvi F, Casagrande S, Bisogni G, Calabrese D, Vanoli F, Di Iorio G, Antonini G, Santoro L, Mauro A, Grandis M, Di Girolamo M, Fabrizi GM, Pareyson D, Sabatelli M, Perfetto F, Rapezzi C, Merlini G, Mazzeo A, Vita G. ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid 2020;27:259-65. [PMID: 32696671 DOI: 10.1080/13506129.2020.1794807] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
8 Gorevic P, Franklin J, Chen J, Sajeev G, Wang JCH, Lin H. Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy. Expert Opin Pharmacother 2021;22:121-9. [PMID: 32892660 DOI: 10.1080/14656566.2020.1811850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Dardiotis E, Andreou S, Aloizou AM, Panayiotou E, Siokas V, Ioannou MN, Vounou E, Christodoulou K, Tanteles GA, Michaelides D, Kyriakides T. The frequency of central nervous system complications in the Cypriot cohort of ATTRV30M neuropathy transplanted patients. Neurol Sci 2020;41:1163-70. [PMID: 31897943 DOI: 10.1007/s10072-019-04176-9] [Reference Citation Analysis]
10 Russo M, Gentile L, Toscano A, Vita G, Mazzeo A. From a misdiagnosis of anorexia nervosa to a dramatic patisiran-induced improvement in a patient with ATTRE89Q amyloidosis. Amyloid 2020;27:279-80. [PMID: 32515606 DOI: 10.1080/13506129.2020.1773425] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Manganelli F, Fabrizi GM, Luigetti M, Mandich P, Mazzeo A, Pareyson D. Hereditary transthyretin amyloidosis overview. Neurol Sci 2020. [PMID: 33188616 DOI: 10.1007/s10072-020-04889-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Minutoli F, Di Bella G, Mazzeo A, Laudicella R, Gentile L, Russo M, Vita G, Baldari S. Serial scanning with 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid (99mTc-DPD) for early detection of cardiac amyloid deposition and prediction of clinical worsening in subjects carrying a transthyretin gene mutation. J Nucl Cardiol 2019. [PMID: 31741327 DOI: 10.1007/s12350-019-01950-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Urits I, Swanson D, Swett MC, Patel A, Berardino K, Amgalan A, Berger AA, Kassem H, Kaye AD, Viswanath O. A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis. Neurol Ther 2020;9:301-15. [PMID: 32785879 DOI: 10.1007/s40120-020-00208-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
14 Magliano L, Obici L, Sforzini C, Mazzeo A, Russo M, Cappelli F, Fenu S, Luigetti M, Tagliapietra M, Gemelli C, Leonardi L, Tozza S, Pradotto LG, Citarelli G, Mauro A, Manganelli F, Antonini G, Grandis M, Fabrizi GM, Sabatelli M, Pareyson D, Perfetto F, Merlini G, Vita G; ATTRv Collaborators. Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy. Orphanet J Rare Dis 2021;16:163. [PMID: 33827635 DOI: 10.1186/s13023-021-01812-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Maruyama R, Yokota T. Molecular Diagnosis and Novel Therapies for Neuromuscular Diseases. J Pers Med 2020;10:E129. [PMID: 32947786 DOI: 10.3390/jpm10030129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Federico A. Rare Neurologic Diseases and Neurological Sciences: a report for the celebration of the 2020 Rare Diseases Day. Neurol Sci 2020;41:491-5. [PMID: 32062737 DOI: 10.1007/s10072-020-04287-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Gentile L, Russo M, Luigetti M, Bisogni G, Di Paolantonio A, Romano A, Guglielmino V, Arimatea I, Sabatelli M, Toscano A, Vita G, Mazzeo A. Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy. Brain Sci 2021;11:515. [PMID: 33921571 DOI: 10.3390/brainsci11040515] [Reference Citation Analysis]
18 Prukop T, Wernick S, Boussicault L, Ewers D, Jäger K, Adam J, Winter L, Quintes S, Linhoff L, Barrantes-Freer A, Bartl M, Czesnik D, Zschüntzsch J, Schmidt J, Primas G, Laffaire J, Rinaudo P, Brureau A, Nabirotchkin S, Schwab MH, Nave KA, Hajj R, Cohen D, Sereda MW. Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats. J Neurosci Res 2020;98:1933-52. [PMID: 32588471 DOI: 10.1002/jnr.24679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Russo M, Gentile L, Toscano A, Aguennouz M, Vita G, Mazzeo A. Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects. Brain Sci 2020;10:E952. [PMID: 33316911 DOI: 10.3390/brainsci10120952] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Al Shaer D, Al Musaimi O, Albericio F, de la Torre BG. 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals (Basel) 2020;13:E40. [PMID: 32151051 DOI: 10.3390/ph13030040] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 10.5] [Reference Citation Analysis]
21 Gentile L, Russo M, Fabrizi GM, Taioli F, Ferrarini M, Testi S, Alfonzo A, Aguennouz M, Toscano A, Vita G, Mazzeo A. Charcot-Marie-Tooth disease: experience from a large Italian tertiary neuromuscular center. Neurol Sci 2020;41:1239-43. [PMID: 31902012 DOI: 10.1007/s10072-019-04219-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
22 Bansal P, Arora M. Small Interfering RNAs and RNA Therapeutics in Cardiovascular Diseases. Adv Exp Med Biol 2020;1229:369-81. [PMID: 32285425 DOI: 10.1007/978-981-15-1671-9_23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Roy B, Griggs R. Advances in Treatments in Muscular Dystrophies and Motor Neuron Disorders. Neurol Clin 2021;39:87-112. [PMID: 33223091 DOI: 10.1016/j.ncl.2020.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
24 de Souza PVS, Badia BML, Farias IB, Pinto WBVR, Oliveira ASB. Acute Hepatic Porphyria: Pathophysiological Basis of Neuromuscular Manifestations. Front Neurosci 2021;15:715523. [PMID: 34646118 DOI: 10.3389/fnins.2021.715523] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Lamb YN, Deeks ED. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy. Drugs 2019;79:863-74. [DOI: 10.1007/s40265-019-01129-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]